Retatrutide 30 | CN Warehouse | Cosmetic Peptides | 99% Purity | 30mg Vials | Lyophilized Powder
TDS
149714-25-0
High Purity Grade
99%
Shenzhen
Tong Peptides
10mg/vial, 10 vials/box
2026-09-07
retatrutide,TB-500,GHK-CU,peptide
-
Product Description
-
Seller Information
-
Description5-diphospho-1D-myo-inositol pentakisphosphate is a myo-inositol pentakisphosphate that consists of 1D-myo-inositol having the five phospho groups located at positions 1, 2, 3, 4 and 6 as well as a diphospho group at position 5. It has a role as a human metabolite. It derives from a myo-inositol. It is a conjugate acid of a 5-diphospho-1D-myo-inositol pentakisphosphate(13-).CertificatesBasic Info
-
Product Name:
diphosphoric acid, mono[(1alpha,2beta,3alpha,4alpha,5alpha,6beta)-2,3, 4,5,6-pentakis(phosphonooxy)cyclohexyl] ester
Other Name:diphosphoric acid, mono[(1alpha,2beta,3alpha,4alpha,5alpha,6beta)-2,3, 4,5,6-pentakis(phosphonooxy)cyclohexyl] ester;5beta[32p] 5Pp-ip5;5beta[32p]-Ip7;5Pp-ip5;Diphosphoinositol pentakisphosphate;Myo-inositol, 1,2,3,4,6-pentakis(dihydrogen phosphate) 5-(trihydrogen diphosphate) (9ci);myo-Inositol, 1,2,3,4,6-pentakis(dihydrogen phosphate) 5-(trihydrogen diphosphate);1-PP-myo-InsP5
CAS No.:149714-25-0
Molecular Formula:C6H19O27P7
InChIKeys:UPHPWXPNZIOZJL-UYSNGIAKSA-N
Molecular Weight:740.02
Exact Mass:739.8277043 g/mol
DSSTox ID:DTXSID00332070
Categories:
Characteristics-
PSA:
447 Ų
Density:2.458±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted)
Boiling Point:1246.106±75.00 °C(Press: 760.00 Torr)(predicted)
PKA:1.406±0.10(predicted)
Research-
Class:
Triple agonist — GCGR, GIPR, GLP-1R
Status:Investigational (Phase 3)
Mechanism:Simultaneously activates glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). Engineered from the native GIP backbone with amino acid substitutions to confer GCGR and GLP-1R activity.
EC50 (Human GCGR):5.79 nM
EC50 (Mouse GIPR):0.191 nM
EC50 (Mouse GLP1R):0.794 nM
EC50 (Mouse GCGR):2.32 nM
EC50 (Human GLP1R):0.775 nM
EC50 (Human GIPR):0.0643 nM
Source:Jastreboff AM, et al. N Engl J Med. 2023;389(6):514-526.DOI
Clinical Development:
References-
ChEMBL:DrugBank:KEGG DRUG:PubChem:Disclaimer:
Retatrutide is an investigational compound not yet approved by FDA or EMA. This listing is for industrial and laboratory research use only. Product information on ECHEMI is provided for sourcing and specification reference. It is not medical advice, a clinical recommendation, or an approved therapy description. Always verify regulatory status, purity, and intended use with the supplier and applicable authorities before purchase or use.
-
-
Seller Information
-
Business Type:
Manufactory
-
Main Products:
retatrutide,TB-500,GHK-CU,peptide
-
Location:
1-1, Kailuo Road, Taojia Town, Jiulongpo District, Chongqing
-
Payment Terms:
TT against copy of documents,L/C,TT against B/L draft before shipment,100% TT in advance
-
Total Annual Revenue:
$10 million-$25 million
-
Total Employees:
501-1000
-
Year of Establishment:
2023
-
-
Country Product Purchase Quantity Date Posted Post an enquiry for this product
